Abstract:Immune thrombocytopenic purpura (ITP) is a blood disorder characterized by the immune-facilitated destruction of platelets by autoantibodies and insistently lowered platelets in the blood. Bleeding can occur more easily when there are too few platelets that play a key role in blood clotting. [ 1 ] This disease was previously known as Werlhof disease. The British Society of Hematology guidelines defined this syndrome as "an autoimmune disorder that causes a low platelet count due to autoantibodies binding to platelet antigens." This leads to premature destruction of platelets by the reticuloendothelial system, particularly in the spleen and sometimes in the liver. [ 1 , 2 ] Patients may be asymptomatic at presentation or present with mild mucocutaneous or life-threatening bleeding. [ 3 ] There is a 15% probability of severe bleeding involving hospitalization within 5 years of diagnosis of ITP, even though only 5% of patients are present with severe bleeding at diagnosis. Notably, the risk of severe bleeding in ITP is not uniform. Certain factors, such as a depleted platelet count, history of hemorrhage, and certain comorbidities can increase the risk of severe bleeding in ITP patients. [ 4 ] Several drugs have been linked with the onset of ITP by triggering the production of autoantibodies (anti-platelets) in some people, including acetazolamide, aspirin, digitoxin, methyldopa, sulfamethazine, cephalothin, rifampin, phenytoin carbamazepine, meprobamate, and quinidine. The development of autoantibodies against platelets has been suggested as a major cause of ITP. [ 5 ]

Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)

Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)

Autoimmune Effector Mechanisms Associated with a Defective Immunosuppressive Axis in Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management

Immune thrombocytopenia (ITP): historical perspectives, pathophysiology, and treatment advances

Immune thrombocytopenia: a review on the pathogenetic role of immune cells

Advances in the pathophysiology of primary immune thrombocytopenia

Platelets in ITP: Victims in Charge of Their Own Fate?

Multi-dysfunctional pathophysiology in ITP

Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management

Immune thrombocytopenic purpura

[Recent progress in immune thrombocytopenia pathophysiology and treatment]

A Review of Pathogenesis and Treatment Options

Treatments for Primary Immune Thrombocytopenia: A Review

Cellular immune dysfunction in immune thrombocytopenia (ITP)

Advances in Immunopathogenesis of Adult Immune Thrombocytopenia

Novel treatments for immune thrombocytopenia: targeting platelet autoantibodies

Recent advances in the management of immune thrombocytopenic purpura (ITP): A comprehensive review

Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters

Novel therapies for immune thrombocytopenia

Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment